Broad PTM Resolution for the Next Era of Biomarker Discovery
- Limitations of today’s genomic and abundance-based biomarkers
- Moving from static molecular snapshots to dynamic protein states and PTMs
- Proteoform-resolved patient stratification to enable more predictive Rx-Dx co-development
- Building pharma partnerships around functionally informed precision medicine
- Pathway from PTM discovery to CDx-ready signatures